|1.||Cai, Sui Xiong: 1 article (01/2006)|
|2.||Juretschke, Hans-Paul: 1 article (08/2003)|
|3.||Petty, Margaret A: 1 article (08/2003)|
|4.||Wettstein, Joseph G: 1 article (08/2003)|
|5.||Neumann-Haefelin, Claudia: 1 article (08/2003)|
|6.||Kalisch, Juergen: 1 article (08/2003)|
|7.||Sarhan, Shakir: 1 article (08/2003)|
|8.||Ikonomidou, Chrysanthy: 1 article (10/2002)|
|9.||Turski, Lechoslaw: 1 article (10/2002)|
|10.||Russell, B R: 1 article (03/2001)|
03/01/1999 - "A similar improvement in National Institutes of Health Stroke Scale scores over time was seen in both the placebo group and the licostinel-treated patients. "
03/01/1999 - "In this 5-center dose escalation trial, patients were enrolled within 48 hours of an ischemic stroke and treated with ascending doses of a short infusion of licostinel or a placebo. "
03/01/1999 - "The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of licostinel in patients with acute stroke. "
01/01/2006 - "The clinical trial of ACEA-1021 for stroke was discontinued, mainly due to low solubility and lack of metabolism of the drug that led to the observation of crystals in the urine of some of the patients. "
08/01/2003 - "The consistent anti-ischemic effects of ACEA 1021 make it a valuable compound for exploratory stroke research."
|2.||Brain Ischemia (Cerebral Ischemia)
06/01/1998 - "Our results suggest that these additional effects of ACEA 1021 may contribute to its anticonvulsive properties in mice as well as to its neuroprotective properties in animal models of cerebral ischemia."
03/24/1997 - "The previously demonstrated neuroprotective property of ACEA 1021 during focal cerebral ischemia cannot be attributed to reduction of spontaneous depolarization in the ischemic penumbra."
01/01/2006 - "The robust efficacy of glycine/NMDA antagonists, such as ACEA-1021 (5), in animal model of brain ischemia, together with good safety profile in animal models and in clinical trials, suggested that this class of NMDA antagonists should have good chance of success in the clinic as neuroprotectants. "
03/01/1999 - "Licostinel (ACEA 1021; 5-nitro-6, 7-dichloro-2,3-quinoxalinedione), a competitive antagonist of glycine at the N-methyl-D-aspartate (NMDA) receptor, is an effective neuroprotective agent in animal models of cerebral ischemia. "
08/01/2003 - "The neuroprotective activity of ACEA 1021 (5-nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione; licostinel), a selective antagonist at the strychnine-insensitive glycine site associated with the NMDA receptor complex, has been investigated in various models of focal cerebral ischemia. "
01/01/2000 - "IT administration of acea-1021 decreased incision-induced pain behaviors in this rat model. "
12/16/1996 - "Nevertheless, intrathecal administration of ACEA-1021 showed equally potent attenuation of nociceptive responses in both animal models of pain. "
01/01/2000 - "These data, coupled with previous studies, suggest that inhibition of pain behaviors by it acea-1021 is produced by blockade of spinal non-NMDA receptors."
|5.||Subdural Hematoma (Subdural Hemorrhage)
|2.||Glycine (Aminoacetic Acid)
|4.||Glutamic Acid (Glutamate)
|5.||Glycine Receptors (Glycine Receptor)
|6.||N-Methyl-D-Aspartate Receptors (NMDA Receptors)
|7.||Ion Channels (Ion Channel)
|2.||Induced Hyperthermia (Thermotherapy)